BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

299 related articles for article (PubMed ID: 30073392)

  • 21. Use of hypomethylating agents and associated care in patients with myelodysplastic syndromes: a claims database study.
    Hatoum HT; Lin SJ; Buchner D; Kim E
    Curr Med Res Opin; 2011 Jun; 27(6):1255-62. PubMed ID: 21554144
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment sequence of lenalidomide and hypomethylating agents and the impact on clinical outcomes for patients with myelodysplastic syndromes.
    Zeidan AM; Klink AJ; McGuire M; Feinberg B
    Leuk Lymphoma; 2019 Aug; 60(8):2050-2055. PubMed ID: 30636526
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
    Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Real-world use and outcomes of hypomethylating agent therapy in higher-risk myelodysplastic syndromes: why are we not achieving the promise of clinical trials?
    Zeidan AM; Salimi T; Epstein RS
    Future Oncol; 2021 Dec; 17(36):5163-5175. PubMed ID: 34636250
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison between decitabine and azacitidine for the treatment of myelodysplastic syndrome: a meta-analysis with 1,392 participants.
    Xie M; Jiang Q; Xie Y
    Clin Lymphoma Myeloma Leuk; 2015 Jan; 15(1):22-8. PubMed ID: 25042977
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hematologic outcomes of myelodysplastic syndromes treatment with hypomethylating agents in community practice.
    Bordoni RE; Feinberg BA; Gilmore JW; Haislip S; Jackson JH; Farrelly E; Kim E; Buchner D
    Clin Lymphoma Myeloma Leuk; 2011 Aug; 11(4):350-4. PubMed ID: 21816373
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Comparison between 5-day decitabine and 7-day azacitidine for lower-risk myelodysplastic syndromes with poor prognostic features: a retrospective multicentre cohort study.
    Lee BH; Kang KW; Jeon MJ; Yu ES; Kim DS; Choi H; Lee SR; Sung HJ; Kim BS; Choi CW; Park Y
    Sci Rep; 2020 Jan; 10(1):39. PubMed ID: 31913293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Quantification of outpatient management and hospitalization of patients with high-risk myelodysplastic syndrome treated with low-dose decitabine.
    Pitako JA; Haas PS; Van den Bosch J; Müller-Berndorff H; Kündgen A; Germing U; Wijermans PW; Lübbert M
    Ann Hematol; 2005 Dec; 84 Suppl 1():25-31. PubMed ID: 16292666
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Hypomethylating Agent Therapy in Myelodysplastic Syndromes With Chromosome 3 Abnormalities.
    Sallman DA; Barnard J; Al Ali NH; Garcia-Manero G; Sekeres MA; DeZern A; Steensma DP; Roboz G; Jabbour E; Maciejewski JP; Pierce S; Padron E; Lancet JE; Kantarjian H; List AF; Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20(9):e597-e605. PubMed ID: 32303488
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Searching for a Light at the End of the Tunnel? Beyond Hypomethylating Agents in Myelodysplastic Syndromes.
    Komrokji RS
    Am Soc Clin Oncol Educ Book; 2016; 35():e345-52. PubMed ID: 27249741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients.
    Wijermans P; Lübbert M; Verhoef G; Bosly A; Ravoet C; Andre M; Ferrant A
    J Clin Oncol; 2000 Mar; 18(5):956-62. PubMed ID: 10694544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Dynamics of PD-1 expression are associated with treatment efficacy and prognosis in patients with intermediate/high-risk myelodysplastic syndromes under hypomethylating treatment.
    Geng S; Xu R; Huang X; Li M; Deng C; Lai P; Wang Y; Wu P; Chen X; Weng J; Du X
    Front Immunol; 2022; 13():950134. PubMed ID: 36003379
    [TBL] [Abstract][Full Text] [Related]  

  • 33. No clear survival benefit of azacitidine for lower-risk myelodysplastic syndromes: A retrospective study of Nagasaki.
    Toriyama E; Hata T; Yokota KI; Chiwata M; Kamijo R; Hashimoto M; Taguchi M; Horai M; Matsuo M; Matsuo E; Takasaki Y; Kawaguchi Y; Itonaga H; Sato S; Ando K; Sawayama Y; Taguchi J; Imaizumi Y; Tsushima H; Jo T; Yoshida S; Moriuchi Y; Miyazaki Y
    Cancer Sci; 2020 Dec; 111(12):4490-4499. PubMed ID: 32939867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of Higher-Risk Myelodysplastic Syndromes After Failure of Hypomethylating Agents.
    Komrokji RS
    Clin Lymphoma Myeloma Leuk; 2015 Jun; 15 Suppl():S56-9. PubMed ID: 26297279
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pre-transplantation cytoreduction does not benefit advanced myelodysplastic syndrome patients after myeloablative transplantation with grafts from family donors.
    Sun YQ; Xu LP; Liu KY; Zhang XH; Yan CH; Jin J; Huang XJ; Wang Y
    Cancer Commun (Lond); 2021 Apr; 41(4):333-344. PubMed ID: 33566460
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Economic analysis of decitabine versus best supportive care in the treatment of intermediate- and high-risk myelodysplastic syndromes from a US payer perspective.
    Pan F; Peng S; Fleurence R; Linnehan JE; Knopf K; Kim E
    Clin Ther; 2010 Dec; 32(14):2444-56. PubMed ID: 21353113
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Optimizing the use of hypomethylating agents in myelodysplastic syndromes: Selecting the candidate, predicting the response, and enhancing the activity.
    Madanat Y; Sekeres MA
    Semin Hematol; 2017 Jul; 54(3):147-153. PubMed ID: 28958288
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Persistence to hypomethylating agents and clinical and economic outcomes among patients with myelodysplastic syndromes.
    Cheng WY; Satija A; Cheung HC; Hill K; Wert T; Laliberté F; Lefebvre P
    Hematology; 2021 Dec; 26(1):261-270. PubMed ID: 33631084
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical Impact of Hypomethylating Agents in the Treatment of Myelodysplastic Syndromes.
    Finelli C; Follo MY; Stanzani M; Parisi S; Clissa C; Mongiorgi S; Barraco M; Cocco L
    Curr Pharm Des; 2016; 22(16):2349-57. PubMed ID: 26960675
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.